ClinicalTrials.gg
RecruitingNCT06457906SHARPUpdated Oct 8, 2026

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC

A Phase 3 interventional study of Experimental group (SRS/SRT/Hypo-RT) and Controled group (HA-WBRT) in Small-cell Lung Cancer, Brain Metastases and SRS, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2023, registered Jun 2024).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
340
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 182 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
61st of 333
340 · median 63
Started
2023
with 36 others
Phase 3
57 of 365
23 open now
Primary completion
2027-08
later than 115 of 214 live
Registered
221st of 365
by date
Lead sponsor
7 of 365
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 61st largest by planned enrollment of the 333 interventional ones that give a count, is one of 37 that started in 2023, is one of 57 in phase 3, reaches primary completion later than 115 of the 214 other live ones, and was the 221st registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

182 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

177 more — sign in →

All 182 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain.

Read the detailed description

Small cell lung cancer (SCLC) is the most aggressive histologic subtype of lung cancer, with a predilection for early metastases. Brain metastases (BM) are a significant threat to quality of life in patients with SCLC. Stereotactic radiosurgery (SRS)/ Stereotactic Radiotherapy (SRT) is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to the surrounding normal tissue. Thus SRS/SRT has now emerged as the preferred treatment modality, either alone or in combination with other modalities for BM. However, given the propensity for dissemination of SCLC, SRS/SRT does not appear to be a rational approach to this pathology. Recently, in selected patients, whole brain radiotherapy (WBRT) has been omitted from the initial management for BM with the aim of reducing the potential risk of delayed neurological toxicity[1-3]. Thus, the role of upfront focal treatment by means of SRS for BM from SCLC has yet to be determined

This phase III trial compares the effect of upfront local treatment (including SRS/SRT and hypofractionated radiotherapy [Hypo-RT]) and WBRT that avoids the hippocampus (the memory zone of the brain) for the treatment of no more than 10 BM in SCLC patients. The expectation is that SRS/SRT/Hypo-RT will be one of standard upfront local treatments in SCLC patients with no more than 10 BM.

Eligible patients will be 1:1 randomized to receive ether local treatment (SRS/SRT/Hypo-RT), or hippocampal-voidance WBRT. The prescription dose of SRS/SRT is 18-22Gy in 1 fraction, 27Gy in 3 fractions and 30Gy in 5 fractions. The prescription dose of Hypo-RT is 40Gy in 8 fraction. The prescription dose of HA-WBRT is 30Gy in 10 fraction. The prescription dose could be adjusted if lesions are located in brain stem when treat with SRS/SRT/Hypo-RT.

03

Conditions studied

  • Small-cell Lung Cancer
  • Brain Metastases
  • SRS
  • Stereotactic Radiotherapy
  • Whole Brain Radiotherpay
  • Hippocampal-avoidance

Keywords

  • Small-cell Lung Cancer
  • Brain Metastases
  • SRS
  • Stereotactic radiotherapy
  • Whole brain radiotherpay
  • Hypofractionaed radiotherapy
  • Hippocampal-avoidance
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Investigators should consider these factors when selecting patients for this trial. Investigators also should consider all other relevant factors (medical and non-medical), as well as the risks and benefits of the study therapy, when deciding if a patient is an appropriate candidate for this trial.

  1. Adult patients (18-80 years of age) with performance status 0-2 or performance score ≥ 70, expected life time more than 6 months;
  2. Pathologically (histologically or cytologically) proven diagnosis of small cell lung cancer within 5 years of registration. If the original histologic proof of is greater than 5 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic or ). Patients with de novo or recurrent small cell lung cancer are permitted;
  3. No more than 10 brain lesions with ≤5 cm in largest diameter and ≤150 ml in treated volume, confirmed by a high-resolution (thickness ≤2mm) , 3-dimensional T1-weighted postgadolinium magnetic resonance imaging (MRI) brain scan within 2 weeks of study initiation. All brain metastases must be outside a 5-mm margin around either hippocampus or optic pathways.
  4. Not all metastatic brain lesions are recommended or suitable for surgical resection after multidisciplinary team discussion. If part of metastatic brain lesions are resected, the patient is permitted for enrollment evaluation at least two weeks after resection; 5 Patients must have the psychological ability and general health that permits completion of the study requirements, all assessment (HVLT-R, , EORTC QLQ-C30) and required follow up (at least 6 months);

6. At least one measurable BM according to the Version 1.1 (RECIST 1.1) criteria; 7. Women of and men who are sexually active should be willing and able to use medically acceptable forms of during treatment on this study and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child; 8. Written (must be available before enrolment in the trial).

Exclusion criteria

Exclusion Criteria:

  1. Clinical or radiologic evidence of new, untreated, and/or progressive prior to registration;
  2. Previous radiotherapy of the brain;
  3. Patients can not tolerate immobilization or are with MRI (i.e., cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants);
  4. Radiographic evidence of hydrocephalus or other architectural distortion of the ventricular system, , increased intracranial pressure requiring immediate depression surgery.
  5. Patients who have not yet recovered from acute high-grade (≥Grade 3) toxicities of prior therapies according Common Terminology Criteria for Adverse EventsVersion5.0 (CTC 5.0);
  6. Presence of other serious illnesses such as acute myocardial infarction, severe arrhythmia, or psychiatric disorders within the past 6 months;
  7. Known carcinoma \< 5 years ago (excluding carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy;
  8. Pregnant or lactating women;
  9. Participation in another clinical study or observation period of competing trials, respectively;
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
340 participants (estimated)

Study arms

  • Experimental
    SRS/SRT/Hypo-RT group

    The patients in this group will receive local treatment for BM.

    Combination Product: Experimental group (SRS/SRT/Hypo-RT)

  • Active comparator
    HA-WBRT group

    The patients in this group will receive HA-WBRT.

    Radiation: Controled group (HA-WBRT)

Interventions

  • Combination productExperimental group (SRS/SRT/Hypo-RT)

    The prescription dose of SRS/SRT is 18-22Gy in 1 fraction, 27Gy in 3 fractions and 30Gy in 5 fractions. The prescription dose of Hypo-RT is 40Gy in 8 fraction. The prescription dose could be adjusted if lesions are located in brain stem when treat with SRS/SRT/Hypo-RT.

  • RadiationControled group (HA-WBRT)

    The prescription dose of HA-WBRT is 30Gy in 10 fraction.

06

What researchers measure

Primary outcomes

  1. Cognitive function scores

    Hopkins Verbal Learning Test-Revised (HVLT-R) total recall score at 6 months after radiotherapy

    Time frame: At 6 months after radiotherapy.

  2. Meadian OS time

    The time that half of enrolled patients died.

    Time frame: Measured at months 3, 6, 9, 12, 15,18, 21, 24, 30, 36,42,48,60 months after radiotherapy

Secondary outcomes

  1. Cognitive function scores

    The Montreal cognitive assessment (MoCA) score at 3 ,6,9,12 months after radiotherapy

    Time frame: Measured at months 3, 6, 9, 12months after radiotherapy

  2. Scores of quality of life

    The European organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) score at 3,6,9,12 months after radiotherapy

    Time frame: Measured at months 3, 6, 9, 12months after radiotherapy

  3. The time of neurological progression free survival

    The time that ≥3 points reduced of HVLT-R total recall score or MoCA score after radiotherapy

    Time frame: Measured at months 3, 6, 9, 12months after radiotherapy

  4. The time of intracranial overall progression free survival

    The time that half of enrolled patients had intracranial relapse

    Time frame: Measured at months 3, 6, 9, 12, 15,18, 21, 24, 30, 36,42,48,60 months after radiotherapy

  5. The time of overall progression free survival

    The time that half of enrolled patients had relapse

    Time frame: Measured at months 3, 6, 9, 12, 15,18, 21, 24, 30, 36,42,48,60 months after radiotherapy

  6. The rate and grade of treatment related toxicity

    All adverse events of enrolled patients after radiotherapy evaluated by CTCAE 5.0

    Time frame: Measured at months 3, 6, 9, 12, 15,18, 21, 24, 30, 36,42,48,60 months after radiotherapy

07

Study locations

1 of 1 sites recruiting
  • Nan Bi
    Beijing, Beijing Municipality 100021, China
    Recruiting
08

References and documents

Publications

  • Yomo S, Hayashi M. Upfront stereotactic radiosurgery in patients with brain metastases from small cell lung cancer: retrospective analysis of 41 patients. Radiat Oncol. 2014 Jul 8;9:152. doi: 10.1186/1748-717X-9-152. PubMed 25005424 ↗
  • Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, Akabane A, Sato Y, Niranjan A, Faramand AM, Lunsford LD, McInerney J, Tuanquin LC, Zacharia BE, Chiang V, Singh C, Yu JB, Braunstein S, Mathieu D, Touchette CJ, Lee CC, Yang HC, Aizer AA, Cagney DN, Chan MD, Kondziolka D, Bernstein K, Silverman JS, Grills IS, Siddiqui ZA, Yuan JC, Sheehan JP, Cordeiro D, Nosaki K, Seto T, Deibert CP, Verma V, Day S, Halasz LM, Warnick RE, Trifiletti DM, Palmer JD, Attia A, Li B, Cifarelli CP, Brown PD, Vargo JA, Combs SE, Kessel KA, Rieken S, Patel S, Guckenberger M, Andratschke N, Kavanagh BD, Robin TP. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study. JAMA Oncol. 2020 Jul 1;6(7):1028-1037. doi: 10.1001/jamaoncol.2020.1271. PubMed 32496550 ↗
  • Robin TP, Jones BL, Amini A, Koshy M, Gaspar LE, Liu AK, Nath SK, Kavanagh BD, Camidge DR, Rusthoven CG. Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer. Lung Cancer. 2018 Jun;120:88-90. doi: 10.1016/j.lungcan.2018.03.027. Epub 2018 Apr 2. PubMed 29748022 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Aug 2027, 47 months after the start.

Of 68 phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 48. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 13, 2024
StartActual
Sep 1, 2023
Primary completionEst.
Aug 30, 2027
CompletionEst.
Feb 28, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06457906
Responsible party
Bi Nan (Professor and Director of Thoracic Division, Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences) — Principal investigator
First posted
Jun 13, 2024
Start date
Sep 1, 2023
Primary completion
Aug 30, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Nan Bi, M.D
Contact
binan_email@163.com
+86-10-87787692
Jianyang Wang, M.D
Contact
pkucell@163.com
+86-10-87788876

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion